These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33881974)

  • 1. Does Human Alpha-Synuclein Behave Like Prions?
    Siddique YH
    CNS Neurol Disord Drug Targets; 2021; 20(6):480-486. PubMed ID: 33881974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein Seeding Assay Using Cultured Cells.
    Ogata J; Takemoto D; Shimonaka S; Imai Y; Hattori N
    Methods Mol Biol; 2021; 2322():27-39. PubMed ID: 34043189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?
    Dunning CJ; George S; Brundin P
    Prion; 2013; 7(1):92-7. PubMed ID: 23360753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.
    Vargas JY; Grudina C; Zurzolo C
    Ageing Res Rev; 2019 Mar; 50():89-101. PubMed ID: 30690184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of alpha-synuclein in Parkinson's disease].
    Miklya I; Pencz N; Hafenscher F; Göltl P
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prion Properties of Alpha-Synuclein].
    Schwarzman AL; Senkevich KA; Emelyanov AK; Pchelina SN
    Mol Biol (Mosk); 2019; 53(3):380-387. PubMed ID: 31184602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms.
    Chen M; Mor DE
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease from the gut.
    Liddle RA
    Brain Res; 2018 Aug; 1693(Pt B):201-206. PubMed ID: 29360467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein.
    Goedert M
    Science; 2015 Aug; 349(6248):1255555. PubMed ID: 26250687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?
    Zheng H; Shi C; Luo H; Fan L; Yang Z; Hu X; Zhang Z; Zhang S; Hu Z; Fan Y; Yang J; Mao C; Xu Y
    Neuroscientist; 2021 Aug; 27(4):367-387. PubMed ID: 32729773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons.
    Chmielarz P; Er Ş; Konovalova J; Bandres L; Hlushchuk I; Albert K; Panhelainen A; Luk K; Airavaara M; Domanskyi A
    Mov Disord; 2020 Dec; 35(12):2279-2289. PubMed ID: 32964492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model.
    Taylor-Whiteley TR; Le Maitre CL; Duce JA; Dalton CF; Smith DP
    Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 30926586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo.
    Angot E; Steiner JA; Lema Tomé CM; Ekström P; Mattsson B; Björklund A; Brundin P
    PLoS One; 2012; 7(6):e39465. PubMed ID: 22737239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The concept of alpha-synuclein as a prion-like protein: ten years after.
    Steiner JA; Quansah E; Brundin P
    Cell Tissue Res; 2018 Jul; 373(1):161-173. PubMed ID: 29480459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
    Gadhavi J; Patel M; Bhatia D; Gupta S
    Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.
    Eyal A; Engelender S
    Cell Cycle; 2006 Sep; 5(18):2082-6. PubMed ID: 16969096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.